SYNB1891
- Generic Name
- SYNB1891
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Synlogic
- Target Recruit Count
- 32
- Registration Number
- NCT04167137
- Locations
- 🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸Ohio State University College of Medicine, Columbus, Ohio, United States
🇺🇸University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath